Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib was effective in treating both early and late onset alopecia areata.

A woman with severe angioedema improved significantly after treatment with rituximab.

A Japanese bone marrow transplant patient developed a rare skin cancer possibly linked to long-term use of the medication voriconazole.

BBR-SA nanomedicine is a safe and effective treatment for breast cancer.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Topical calcitriol is safe for preventing hair loss during chemotherapy.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Cutaneous angiosarcomas require a combined treatment approach, but prognosis is generally poor.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Onyx® embolization effectively treats facial arteriovenous malformations with minimal complications.

DA-9401 can protect against finasteride-induced reproductive damage in rats.

Nilotinib can cause skin issues like red bumps and hair loss.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

VDAC2 promotes cell death in cashmere goat hair follicles through the P53 pathway.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

FOL-026 peptide can help repair blood vessels and promote growth, offering potential treatment for vascular diseases.

Combining ciclosporin and simvastatin can cause severe kidney damage.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.